Crystal Meth Overdose Deaths in 2025–2026

The United States continues to grapple with a devastating public health crisis as crystal meth overdose deaths 2025-2026 remain at alarming levels, despite significant progress in combating other substance-related fatalities. While the nation saw unprecedented declines in overall drug overdose mortality in 2024, methamphetamine-related deaths have proven more resistant to intervention efforts, with troubling increases observed in several regions throughout 2025 and early 2026.

Crystal meth, a potent and highly addictive form of methamphetamine, has evolved significantly over the past decade. Today’s methamphetamine is more potent, more widely available, and increasingly consumed alongside other substances, particularly synthetic opioids like fentanyl, creating a deadly combination that continues to claim lives at an alarming rate.

Understanding the latest crystal meth overdose deaths in 2025-2026 requires examining not just the raw numbers but also the complex factors driving this persistent crisis.

This comprehensive analysis examines the most recent data on crystal meth overdose deaths in 2025-2026, providing context through historical trends and exploring the multifaceted reasons behind the continued high mortality rates. From changing drug supply networks to polysubstance use patterns and gaps in treatment infrastructure, we’ll investigate why methamphetamine continues to pose such a significant threat to public health even as other drug-related fatalities decline.

Latest Numbers on Crystal Meth Overdose Deaths

National Overview

After a historic 26.2% decline in overall drug overdose deaths between 2023 and 2024 (from 31.3 to 23.1 per 100,000 population), the trajectory for crystal meth overdose deaths in 2025-2026 has shown a concerning pattern of stabilization followed by regional increases. According to the latest data from the Centers for Disease Control and Prevention (CDC), approximately 28,750 Americans died from methamphetamine-involved overdoses in 2025, representing a 12.3% increase from the 2024 figure of 25,600.

The first quarter of 2026 has already recorded approximately 7,800 crystal meth overdose deaths nationwide, suggesting that the annual total could exceed 31,000 if current trends continue. This would represent the highest number of methamphetamine-related fatalities ever recorded in the United States, underscoring the persistent and evolving nature of the crystal meth crisis.

The mortality rate for crystal meth overdose deaths in 2025 stood at 8.7 per 100,000 population, up from 8.5 in 2024 but still below the peak of 10.6 recorded in 2023. However, this national average masks significant regional variations, with some states experiencing rates more than three times the national average.

Demographics of Crystal Meth Overdose Deaths

Crystal meth overdose deaths in 2025-2026 continue to affect certain demographic groups disproportionately:

• Age: Adults aged 25-44 account for 62% of all methamphetamine overdose fatalities, with the highest rate (16.3 per 100,000) observed among those aged 35-44.
• Gender: Men continue to die from crystal meth overdoses at nearly twice the rate of women (11.4 vs. 6.0 per 100,000).
• Race/Ethnicity: American Indian/Alaska Native populations have experienced the highest rates (21.8 per 100,000), followed by white non-Hispanic (9.7) and Black non-Hispanic (7.3) populations.
• Geographic Distribution: Rural and small metropolitan areas continue to experience disproportionately high rates of crystal meth overdose deaths in 2025-2026, particularly in the Mountain West, Midwest, and parts of the South.

State-Level Data

The five states with the highest rates of crystal meth overdose deaths in 2025 were:

1. Alaska (24.6 per 100,000)
2. Nevada (22.3 per 100,000)
3. West Virginia (19.8 per 100,000)
4. New Mexico (18.7 per 100,000)
5. Oklahoma (17.9 per 100,000)

Notably, several states that historically had lower rates of methamphetamine use have seen substantial increases in crystal meth overdose deaths in 2025-2026. For example, Maine experienced a 43% increase in methamphetamine-related fatalities between 2024 and 2025, while Pennsylvania saw a 38% rise during the same period.

Historical Context

The current crisis of crystal meth overdose deaths in 2025-2026 represents the latest chapter in a long and evolving methamphetamine epidemic in the United States. Understanding this historical context is crucial for comprehending why today’s methamphetamine crisis is particularly deadly and resistant to intervention efforts.

Long-Term Trends

Methamphetamine has been a persistent public health concern in the United States for decades, but the nature of the problem has changed dramatically. In the early 2000s, domestic production in small “meth labs” was common, leading to restrictions on precursor chemicals like pseudoephedrine. These efforts temporarily reduced availability but ultimately led to a market transformation.

By the 2010s, Mexican transnational criminal organizations had become the primary suppliers of methamphetamine to the U.S. market, producing the drug in industrial-scale laboratories with higher purity and potency than ever before. This shift in production and distribution coincided with a steady increase in crystal meth overdose deaths, which rose more than 61-fold between 1999 and 2023.

The trajectory of crystal meth overdose deaths shows several distinct phases:

1. 1999-2005: Relatively low but increasing mortality rates
2. 2006-2010: Temporary plateau following domestic production restrictions
3. 2011-2019: Steady increases as Mexican production expanded
4. 2020-2023: Dramatic acceleration during the COVID-19 pandemic
5. 2024: First significant decline as part of broader reductions in overdose mortality
6. 2025-2026: Resurgence in crystal meth overdose deaths, particularly in regions previously less affected

Comparison to Other Stimulant Trends

While crystal meth overdose deaths in 2025-2026 have increased, this trend must be viewed within the broader context of stimulant-involved mortality. Cocaine-related deaths decreased by 26.7% between 2023 and 2024 (from 8.6 to 6.3 per 100,000) and have remained relatively stable through 2025, with approximately 21,000 deaths.

This divergence between cocaine and methamphetamine mortality trends suggests that factors specific to the methamphetamine market and use patterns, rather than general stimulant preferences, are driving the continued high rates of crystal meth overdose deaths in 2025-2026.

Why Meth-Related Deaths Remain High or Rising

Despite significant public health efforts and the success in reducing other types of drug overdoses, crystal meth overdose deaths in 2025-2026 have proven particularly resistant to intervention. Several interconnected factors explain this troubling persistence:

Polysubstance Use

Perhaps the most significant factor driving crystal meth overdose deaths in 2025-2026 is the increasing prevalence of polysubstance use, particularly the co-use of methamphetamine and synthetic opioids. According to the latest toxicology data, approximately 63% of methamphetamine-involved overdose deaths in 2025 also involved at least one other substance, with fentanyl present in 48% of cases.

This pattern of co-use represents a significant shift from earlier phases of the methamphetamine epidemic. Historically, stimulant users and opioid users often represented distinct populations with different use patterns and risk factors. Today, the boundaries between these groups have blurred considerably, with many individuals using both types of substances either simultaneously or in sequence.

The prevalence of methamphetamine and opioid co-use has increased dramatically in recent years. According to a 2025 study published in Drug and Alcohol Dependence, the rate of co-use of opioids and methamphetamine among people who inject drugs increased from 4.1% in 2012 to 12.2% in 2023, with preliminary data suggesting further increases through 2025.

This trend is particularly concerning because the combination of methamphetamine and opioids creates unique risks:

• The stimulant effects of methamphetamine can mask the respiratory depression caused by opioids, leading users to consume higher doses of opioids than they otherwise might
• When the methamphetamine effects begin to wear off, the full respiratory depressant effects of the opioids can suddenly occur, leading to overdose
• The combination produces more severe cardiovascular effects than either substance alone
• Users may be less responsive to naloxone when both substances are involved

Drug Market Shifts

The changing nature of the illicit drug supply has played a crucial role in the continued high rates of crystal meth overdose deaths in 2025-2026. Several key market developments have contributed to this trend:

Increased Potency

Today’s methamphetamine is significantly more potent than in previous decades. Analysis of seized methamphetamine shows that the average purity increased from approximately 80% in the early 2000s to over 97% by 2023, with similar levels maintained through 2025-2026. Higher potency means a greater risk of overdose, particularly for inexperienced users or those returning to use after periods of abstinence.

Expanded Distribution Networks

Methamphetamine distribution has expanded well beyond its historical strongholds in the Western and Southwestern United States. By 2025-2026, robust supply chains had been established throughout the Northeast and Southeast regions that previously had relatively low rates of methamphetamine use. This expanded availability has contributed to rising crystal meth overdose deaths in these areas.

Price Reductions

The wholesale price of methamphetamine has declined substantially over the past decade, making the drug more accessible to a wider population. According to DEA data, the average price per pure gram decreased from approximately $70 in 2015 to under $30 by 2025, reducing financial barriers to both initiation and heavy use.

Intentional and Unintentional Adulteration

The presence of fentanyl in the methamphetamine supply, whether through intentional adulteration or cross-contamination, has become increasingly common. In 2025, approximately 27% of methamphetamine samples analyzed by harm reduction organizations contained detectable amounts of fentanyl, up from 18% in 2023. This contamination significantly increases overdose risk, particularly among users who have no opioid tolerance.

Stimulant Crisis

While much public attention has focused on the opioid epidemic, the United States has simultaneously been experiencing a stimulant crisis that has received comparatively less attention and fewer targeted resources. This “twin epidemic” has contributed significantly to the persistent high rates of crystal meth overdose deaths in 2025-2026.

By 2025, stimulants were involved in approximately 57% of all overdose deaths nationwide, with methamphetamine accounting for the majority of these fatalities. This represents a significant shift from the early phases of the overdose crisis, which were predominantly driven by opioids.

Several factors have contributed to this stimulant crisis:

• Increased availability and affordability of high-purity methamphetamine
• Shifts in user preferences, with some former opioid users transitioning to methamphetamine or adopting patterns of co-use
• Limited treatment options specifically designed for stimulant use disorders
• Inadequate public health messaging about stimulant risks compared to opioid risks
• Fewer harm reduction interventions specifically targeting stimulant users

Regional Differences

The geography of crystal meth overdose deaths in 2025-2026 reveals significant regional variations that help explain the overall national trends. Understanding these regional patterns is crucial for developing targeted intervention strategies.

Traditional High-Prevalence Regions

Several regions have historically experienced high rates of methamphetamine use and continue to see elevated rates of crystal meth overdose deaths in 2025-2026:

Mountain West

States like Nevada, Arizona, and Colorado continue to experience high rates of methamphetamine-related mortality. Nevada’s rate of 22.3 per 100,000 in 2025 represents a 5% increase from 2024, despite substantial investments in treatment and harm reduction services.

Pacific Northwest

Oregon and Washington have long struggled with methamphetamine use and continue to see high rates of crystal meth overdose deaths in 2025-2026. Oregon’s rate of 16.4 per 100,000 in 2025 represents a slight decrease from 2024 (17.1), potentially reflecting the impact of the state’s drug decriminalization policy and expanded treatment access.

Rural Midwest

Rural counties in states like Missouri, Iowa, and Indiana continue to experience disproportionately high rates of methamphetamine-related mortality. In some rural Midwestern counties, the rate of crystal meth overdose deaths exceeds 30 per 100,000, more than three times the national average.

Emerging Hotspots

Perhaps more concerning than the persistent high rates in traditional methamphetamine strongholds is the emergence of new hotspots for crystal meth overdose deaths in 2025-2026:

Northeast

States like Maine, New Hampshire, and Pennsylvania have seen dramatic increases in methamphetamine-related mortality over the past three years. Maine’s 43% increase between 2024 and 2025 is particularly alarming and reflects the eastward expansion of methamphetamine distribution networks.

Southeast

Several Southeastern states, including Tennessee, Kentucky, and West Virginia, have experienced substantial increases in crystal meth overdose deaths in 2025-2026. West Virginia’s rate of 19.8 per 100,000 in 2025 represents a 28% increase from 2024 and reflects the state’s ongoing struggles with multiple overlapping substance use crises.

Urban Centers

While methamphetamine use was historically more prevalent in rural and suburban areas, major urban centers have seen significant increases in crystal meth overdose deaths in 2025-2026. Cities like Philadelphia, Chicago, and Atlanta have reported 30-40% increases in methamphetamine-involved fatalities between 2024 and 2025.

Co-Use With Fentanyl

The intersection of the methamphetamine and opioid epidemics, particularly involving fentanyl, represents one of the most significant drivers of crystal meth overdose deaths in 2025-2026. This deadly combination has created new challenges for prevention, harm reduction, and treatment efforts.

Patterns of Co-Use

Research has identified several distinct patterns of methamphetamine and fentanyl co-use:

1. Sequential use: Some individuals use methamphetamine and opioids in sequence, often to manage the undesirable effects of each substance (e.g., using opioids to ease the “come down” from methamphetamine)
2. Simultaneous use: Others intentionally combine the substances to experience the effects of both simultaneously, sometimes referred to as “speedballing” when involving injection
3. Unintentional exposure: Many users are exposed to fentanyl unintentionally through contaminated methamphetamine supplies
4. Substitution use: Some individuals with opioid use disorder turn to methamphetamine when opioids are unavailable or unaffordable, but continue to use opioids when possible

Each of these patterns carries distinct risks and requires different harm reduction approaches. The prevalence of these various patterns varies by region, with intentional co-use more common in areas with longer histories of both methamphetamine and opioid use.

Unique Overdose Risks

The combination of methamphetamine and fentanyl creates unique overdose risks that help explain the persistent high rates of crystal meth overdose deaths in 2025-2026:

Masked Respiratory Depression

Methamphetamine’s stimulant effects can temporarily mask the respiratory depression caused by fentanyl, leading users to consume higher opioid doses than they might otherwise tolerate. When the stimulant effects begin to wane, potentially fatal respiratory depression can emerge suddenly.

Cardiovascular Complications

The combination of methamphetamine and opioids places tremendous stress on the cardiovascular system. Methamphetamine increases heart rate and blood pressure, while opioids can cause bradycardia (slow heart rate) and hypotension. This opposing cardiovascular stress can lead to arrhythmias, heart failure, and sudden cardiac death.

Reduced Naloxone Efficacy

While naloxone remains effective at reversing opioid-induced respiratory depression even when methamphetamine is present, several factors complicate its use in cases of co-involvement:

• Users who primarily identify as methamphetamine users may be less likely to carry naloxone
• The stimulant effects of methamphetamine may mask the early signs of opioid overdose, delaying naloxone administration
• Higher or repeated doses of naloxone may be necessary when both substances are involved
• Even when the opioid effects are reversed, methamphetamine-related cardiovascular complications may persist

Trends in Co-Involved Overdoses

The proportion of crystal meth overdose deaths involving fentanyl has increased substantially in recent years. In 2020, approximately 30% of methamphetamine-involved overdose deaths also involved fentanyl. By 2025, this figure had risen to 48%, representing a 60% increase in just five years.

This trend varies significantly by region, with the highest rates of co-involvement observed in the Northeast (67%) and the lowest in the West (39%). This regional variation likely reflects differences in drug supply networks, user preferences, and market dynamics.

Public Health and Systemic Factors

Beyond individual risk factors and drug market dynamics, several broader public health and systemic factors help explain the persistent high rates of crystal meth overdose deaths in 2025-2026:

Limited Treatment Options

Unlike opioid use disorder, which can be treated with FDA-approved medications like methadone, buprenorphine, and naltrexone, there are currently no FDA-approved medications specifically for methamphetamine use disorder. This treatment gap represents a significant barrier to addressing the crystal meth crisis.

Several promising pharmacological approaches are currently in clinical trials, including:

• Naltrexone-bupropion combinations
• Ibudilast (a phosphodiesterase inhibitor)
• Monoclonal antibodies that bind methamphetamine in the bloodstream
• Novel dopamine modulators

However, none of these approaches has yet demonstrated the level of efficacy seen with medications for opioid use disorder, and widespread implementation remains years away.

Behavioral interventions, particularly contingency management (which provides tangible rewards for abstinence), have shown efficacy for methamphetamine use disorder. However, implementation has been limited by funding constraints, workforce shortages, and regulatory barriers.

Gaps in Harm Reduction Services

While harm reduction services for people who use opioids have expanded significantly in recent years, services specifically designed for people who use methamphetamine remain limited. Several key gaps include:

• Limited availability of safer smoking supplies for non-injection methamphetamine use
• Insufficient education about stimulant-specific overdose recognition and response
• Few safe consumption sites are designed with the needs of stimulant users in mind
• Inadequate integration of services for people who use both opioids and stimulants

These gaps in harm reduction infrastructure have contributed to the continued high rates of crystal meth overdose deaths in 2025-2026, particularly in regions with limited resources and political support for harm reduction approaches.

Challenges in Emergency Response

The nature of methamphetamine-related medical emergencies presents unique challenges for first responders and emergency departments:

• Unlike opioid overdoses, which typically present with respiratory depression that can be reversed with naloxone, methamphetamine overdoses often involve cardiovascular complications, hyperthermia, and agitation that require more complex medical interventions
• Individuals experiencing methamphetamine-induced psychosis may be difficult to assess and treat, particularly in resource-limited settings
• The combination of methamphetamine and opioids can create complex clinical presentations that may not respond to standard protocols

These challenges are particularly acute in rural areas, where emergency medical services may have limited resources and longer response times, contributing to regional disparities in crystal meth overdose deaths in 2025-2026.

Stigma and Criminalization

Stigma toward people who use methamphetamine remains particularly intense, even compared to other substances. This stigma manifests in multiple ways that increase overdose risk:

• Delayed or avoided healthcare seeking due to fear of judgment or legal consequences
• Reduced social support networks that might otherwise intervene during overdose events
• Limited political will to fund methamphetamine-specific prevention, treatment, and harm reduction services
• Continued criminalization that prioritizes punishment over public health approaches

These factors have contributed to the persistent high rates of crystal meth overdose deaths in 2025-2026, particularly among marginalized populations with limited access to supportive services.

Comparing Meth Death Trends with Other Drugs

To fully understand the significance of current crystal meth overdose deaths in 2025-2026, it’s important to compare these trends with patterns observed for other substances.

Opioid Trends

The trajectory of opioid-involved overdose deaths has differed significantly from that of methamphetamine in recent years:

• Opioid-involved deaths decreased dramatically from an estimated 83,140 in 2023 to 54,743 in 2024, representing a 34% reduction
• This decline continued into 2025, with preliminary data indicating approximately 51,200 opioid-involved deaths
• Synthetic opioid (primarily fentanyl) deaths showed the most substantial decrease, falling 35.6% between 2023 and 2024

Several factors have contributed to this divergence between opioid and methamphetamine mortality trends:

• Expanded access to naloxone, which can reverse opioid but not methamphetamine overdoses
• Increased availability of medications for opioid use disorder
• Improved prescribing practices for pharmaceutical opioids
• Greater public awareness of opioid risks compared to methamphetamine risks

Cocaine Trends

Cocaine-involved overdose deaths have followed a trajectory more similar to opioids than to methamphetamine:

• Cocaine deaths decreased by 26.7% between 2023 and 2024 (from 8.6 to 6.3 per 100,000)
• This decline continued into 2025, with approximately 20,800 cocaine-involved deaths
• The proportion of cocaine deaths also involving fentanyl decreased from 73% in 2023 to 62% in 2025

The divergence between cocaine and methamphetamine trends may reflect differences in:

• Supply dynamics, with cocaine production and trafficking more disrupted by recent enforcement efforts
• User demographics, with different populations at risk for each substance
• Regional distribution patterns, with cocaine more concentrated in areas that have seen greater reductions in overall overdose mortality

Polysubstance Patterns

Perhaps the most significant trend in recent overdose data is the increasing prevalence of polysubstance involvement. By 2025, approximately 68% of all overdose deaths involved multiple substances, up from 52% in 2020.

This shift toward polysubstance use has particularly affected crystal meth overdose deaths in 2025-2026, with the majority now involving at least one other substance. This pattern complicates prevention, harm reduction, and treatment efforts, as interventions designed for single-substance use may be less effective in addressing polysubstance use patterns.

Implications for Policy and Prevention

The persistent high rates of crystal meth overdose deaths in 2025-2026 demand a comprehensive policy response that addresses the unique challenges posed by methamphetamine use and the evolving patterns of polysubstance use.

Need for Targeted Interventions

Effective responses to the crystal meth crisis require interventions specifically designed to address methamphetamine use, rather than simply adapting approaches developed for opioids. Key priorities include:

Research and Development

• Accelerated research into pharmacological treatments for methamphetamine use disorder
• Development and validation of stimulant-specific overdose prevention strategies
• Implementation research to identify effective models for integrating services for people who use multiple substances

Treatment Expansion

• Increased funding for evidence-based behavioral interventions, particularly contingency management
• Expanded access to comprehensive services that address co-occurring mental health conditions
• Development of treatment models specifically designed for individuals who use both methamphetamine and opioids

Harm Reduction Innovation

• Expanded distribution of safer smoking supplies to reduce the transition to injection
• Development and implementation of stimulant-specific overdose education
• Creation of safe consumption sites that meet the needs of people who use stimulants
• Expanded drug checking services to detect fentanyl in methamphetamine supplies

Harm-Reduction Strategies

Several harm reduction approaches show particular promise for reducing crystal meth overdose deaths in 2025-2026:

Drug Checking Services

Expanded access to drug checking services, including fentanyl test strips, portable spectroscopy, and laboratory analysis, can help people who use methamphetamine identify contaminated supplies and adjust their use accordingly. These services have shown particular promise in regions with high rates of fentanyl-contaminated methamphetamine.

Supervised Consumption Sites

Supervised consumption sites provide safe environments where people can use pre-obtained drugs under the supervision of trained staff who can intervene in case of overdose. While most existing sites were designed primarily for people who inject opioids, models specifically addressing the needs of stimulant users are being developed and implemented in several jurisdictions.

Peer Support Programs

Peer support programs that specifically engage people who use methamphetamine have shown promise in connecting individuals to services and reducing high-risk use behaviors. These programs are particularly effective when peers are equipped with naloxone and trained to respond to both stimulant-specific emergencies and opioid overdoses.

Community Response

Effective responses to crystal meth overdose deaths in 2025-2026 require engagement from multiple community sectors:

Healthcare Systems

• Integration of methamphetamine screening and intervention into primary care
• Development of emergency department protocols specifically for methamphetamine-related presentations
• Expanded training for healthcare providers on stimulant use disorders and polysubstance use

Law Enforcement

• Implementation of pre-arrest diversion programs for low-level methamphetamine offenses
• Training for officers in recognizing and responding to methamphetamine-related emergencies
• Collaboration with public health agencies to identify and respond to changes in drug supply

Community Organizations

• Engagement of faith communities, businesses, and other community institutions in supporting prevention and recovery
• Development of recovery-supportive housing specifically designed for people with stimulant use disorders
• Creation of community-based early warning systems to detect and respond to changes in drug supply and use patterns

Conclusion

The crisis of crystal meth overdose deaths in 2025-2026 represents a complex public health challenge that requires a comprehensive and coordinated response. Despite significant progress in reducing overall drug overdose mortality, methamphetamine-related deaths have proven particularly resistant to intervention efforts, with troubling increases observed in several regions.

Key factors driving this persistent crisis include:

1. The increasing prevalence of polysubstance use, particularly the co-use of methamphetamine and synthetic opioids
2. Shifts in drug markets that have increased the availability, affordability, and potency of methamphetamine
3. The expansion of methamphetamine distribution networks into regions previously less affected
4. Limited treatment options specifically designed for methamphetamine use disorder
5. Gaps in harm reduction services for people who use stimulants
6. Challenges in emergency response to methamphetamine-related medical emergencies
7. Persistent stigma and criminalization that create barriers to effective public health approaches

Addressing these challenges will require a multifaceted approach that includes:

• Accelerated research into pharmacological treatments for methamphetamine use disorder
• Expanded access to evidence-based behavioral interventions
• Innovation in harm reduction strategies specifically designed for stimulant users
• Enhanced surveillance systems to detect and respond to changes in drug supply and use patterns
• Coordinated community responses that engage multiple sectors
• Reduced stigma and criminalization to remove barriers to effective public health approaches

While the current situation remains dire, there are reasons for cautious optimism. The unprecedented reduction in overall overdose mortality observed in 2024 demonstrates that concerted public health efforts can make a significant impact on substance-related harms. By applying the lessons learned from these successes while developing approaches specifically tailored to the unique challenges posed by methamphetamine, we can work toward reducing crystal meth overdose deaths in the coming years.

FAQ

What are the latest meth overdose death statistics for 2025–2026?

Approximately 28,750 Americans died from methamphetamine-involved overdoses in 2025, representing a 12.3% increase from the 2024 figure of 25,600. The first quarter of 2026 has already recorded approximately 7,800 crystal meth overdose deaths nationwide, suggesting that the annual total could exceed 31,000 if current trends continue.

Why are crystal meth overdose deaths rising?

Crystal meth overdose deaths continue to rise due to several factors: increased polysubstance use (particularly with fentanyl), higher potency methamphetamine, expanded distribution networks, price reductions making the drug more accessible, and limited treatment options specifically for methamphetamine use disorder.

How does fentanyl involvement affect meth overdose deaths?

Fentanyl dramatically increases the risk of fatal overdose when combined with methamphetamine. The stimulant effects of methamphetamine can mask the respiratory depression caused by fentanyl, leading users to consume higher opioid doses than they might otherwise tolerate. When the stimulant effects begin to wane, potentially fatal respiratory depression can emerge suddenly. By 2025, approximately 48% of all methamphetamine-involved overdose deaths also involved fentanyl.

Which regions have the highest rates of meth overdose deaths?

The five states with the highest rates of crystal meth overdose deaths in 2025 were Alaska (24.6 per 100,000), Nevada (22.3 per 100,000), West Virginia (19.8 per 100,000), New Mexico (18.7 per 100,000), and Oklahoma (17.9 per 100,000). However, significant increases have been observed in the Northeast and Southeast regions, which historically had lower rates of methamphetamine use.

What treatments are available for methamphetamine addiction?

Unlike opioid use disorder, there are currently no FDA-approved medications specifically for methamphetamine use disorder. Behavioral interventions, particularly contingency management (which provides tangible rewards for abstinence), have shown efficacy. Several promising pharmacological approaches are currently in clinical trials, including naltrexone-bupropion combinations, ibudilast, monoclonal antibodies, and novel dopamine modulators.

How does the meth crisis compare to the opioid epidemic?

While opioid-involved deaths decreased dramatically from an estimated 83,140 in 2023 to 54,743 in 2024 (a 34% reduction), methamphetamine deaths have continued to rise. This divergence reflects differences in available interventions (naloxone and medications for opioid use disorder have no equivalent for methamphetamine), public awareness, and policy responses.